Sigyn Therapeutics (SIGY) Change in Account Payables (2016 - 2025)
Sigyn Therapeutics (SIGY) posted Change in Account Payables of $43758.0 for Q3 2025, down 24.3% sequentially from $57806.0 in Q2 2025, and down 64.5% YoY from $123279.0 in Q3 2024.
Sigyn Therapeutics (SIGY) Change in Account Payables (2016 - 2025) Analysis & Trends
Sigyn Therapeutics has reported Change in Account Payables for 10 years, with the latest figure at $43758.0 in Q3 2025.
- Quarterly Change in Account Payables fell 64.5% year-over-year to $43758.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $161961.0 (down 48.17% YoY) and the FY2024 annual result came in at $146738.0, down 25.37% from the prior year.
- Change in Account Payables declined to $43758.0 in Q3 2025 per SIGY's latest filing, from $57806.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $162517.0 in Q4 2023 and troughed at -$62432.0 in Q1 2023.
- A 5-year average of $43163.1 and a median of $28055.0 in 2021 frame the typical range for Change in Account Payables.
- The widest YoY moves for Change in Account Payables: up 3625.76% in 2021, down 1126.61% in 2021.
- Over 5 years, Change in Account Payables stood at $6800.0 in 2021, then soared by 219.06% to $21696.0 in 2022, then surged by 649.06% to $162517.0 in 2023, then slumped by 102.01% to -$3259.0 in 2024, then surged by 1442.68% to $43758.0 in 2025.
- According to Business Quant data, Change in Account Payables over the past three periods registered $43758.0, $57806.0, and $63656.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Sigyn Therapeutics | 48,161.31 | -37,409.69 | - | 43,758.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 43,758.00 |
| Sep 30, 2025 | 43,758.00 |
| Jun 30, 2025 | 57,806.00 |
| Jun 30, 2025 | 57,806.00 |
| Mar 31, 2025 | 63,656.00 |
| Mar 31, 2025 | 63,656.00 |
| Dec 31, 2024 | -3,259.00 |
| Dec 31, 2024 | -3,259.00 |
| Sep 30, 2024 | 123,279.00 |
| Sep 30, 2024 | 123,279.00 |
| Jun 30, 2024 | -41,086.00 |
| Jun 30, 2024 | -41,086.00 |
| Mar 31, 2024 | 67,804.00 |
| Mar 31, 2024 | 67,804.00 |
| Dec 31, 2023 | 162,517.00 |
| Dec 31, 2023 | 162,517.00 |
| Sep 30, 2023 | 21,685.00 |
| Sep 30, 2023 | 21,685.00 |
| Jun 30, 2023 | 74,859.00 |
| Jun 30, 2023 | 74,859.00 |